You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 6,689,275

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,689,275

Title:	Method and pharmaceutical composition for replacing iron losses in dialysis patients
Abstract:	A method of replacing iron losses during dialysis of patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis solutions, during dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidial ferric compound, preferably ferric pyrophosphate.
Inventor(s):	Gupta; Ajay (Farmington Hills, MI)
Assignee:
Application Number:	08/775,595
Patent Claims:	1. A composition comprising ferric pyrophosphate dissolved in a dialysis solution, wherein the dialysis solution is selected from the group consisting of peritoneal dialysis solution and hemodialysis solution. 2. A method of increasing the amount of bioavailable iron in a mammal by administering to the mammal during dialysis via a peritoneal dialysis solution or hemodialysis solution from 2 to 50 ug iron per deciliter of the peritoneal dialysis solution or hemodialysis solution, said iron in the form of ferric pyrophosphate dissolved in the peritoneal dialysis solution or hemodialysis solution, whereby the amount of bioavailable iron in the mammal is safely increased. 3. A method of iron administration to a dialysis patient through a dialysis solution selected from the group consisting of peritoneal dialysis solution and hemodialysis solution, said method comprising dialyzing the patient with said dialysis solution, wherein said dialysis solution contains from 2 to 50 ug of iron per deciliter of the dialysis solution, said iron in the form of ferric pyrophosphate soluble in the dialysis solution, whereby iron is safely administered to the patient via the dialysis solution. 4. A method of increasing the amount of bioavailable iron in a mammal by administering to the mammal during dialysis via a hemodialysis solution from 4 to 50 milligrams of iron per dialysis session, said iron in the form of ferric pyrophosphate dissolved in the hemodialysis solutions, whereby the amount of bioavailable iron in the mammal is safely increased.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.